Market research
KUR.F Kura Oncology, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 961M
- P/E ratio
- Not available
- Analyst target
- 44.57
- Dividend yield
- Not available
- Beta
- 0.38
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US50127T1097
- Market cap
- 961M
- P/E ratio
- Not available
- Analyst target
- 44.57
- Dividend yield
- Not available
- Beta
- 0.38
About
About Kura Oncology, Inc
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the KUR.F discussion.
5 years, 4 months ago
Kura Oncology, Inc is currently in a long term downtrend where the price is trading 33.8% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Kura Oncology, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 46.4% to $-26M since the same quarter in the previous year.
Finally, its free cash flow fell by 33.4% to $-19M since the same quarter in the previous year.
Based on the above factors, Kura Oncology, Inc gets an overall score of 1/5.